๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Metastatic, hormone refractory prostate cancer: a randomised phase II study of the endothelin-a receptor antagonist atrasentan

โœ Scribed by C. Schulman; P. Abrahamsson; R. Humerickhouse; M. Weinberg; J. Schmitt; A. Nabulsi

Book ID
118643991
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
202 KB
Volume
1
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
โœ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 142 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelinโ€A receptor antagonist, in patients with metastatic hormoneโ€refractory prostate cancer (HRPC). ## METHODS. This multinational, doubleโ€blind, placeboโ€contro